KR950700317A - 유두종 바이러스의 안티센스 올리고뉴클레오티드 저해(antisense oligonucleotide inhibition of papillomavirus) - Google Patents
유두종 바이러스의 안티센스 올리고뉴클레오티드 저해(antisense oligonucleotide inhibition of papillomavirus)Info
- Publication number
- KR950700317A KR950700317A KR1019940703131A KR19940703131A KR950700317A KR 950700317 A KR950700317 A KR 950700317A KR 1019940703131 A KR1019940703131 A KR 1019940703131A KR 19940703131 A KR19940703131 A KR 19940703131A KR 950700317 A KR950700317 A KR 950700317A
- Authority
- KR
- South Korea
- Prior art keywords
- antisense oligonucleotide
- oligonucleotide inhibition
- papillomavirus
- papilloma virus
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/860,925 US5457189A (en) | 1989-12-04 | 1992-03-31 | Antisense oligonucleotide inhibition of papillomavirus |
US7/860,925 | 1992-03-31 | ||
PCT/US1993/003075 WO1993020095A1 (en) | 1992-03-31 | 1993-03-31 | Antisense oligonucleotide inhibition of papillomavirus |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950700317A true KR950700317A (ko) | 1995-01-16 |
KR0160185B1 KR0160185B1 (ko) | 1998-11-16 |
Family
ID=25334385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940703131A KR0160185B1 (ko) | 1992-03-31 | 1993-03-31 | 유두종 바이러스의 안티센스 올리고뉴클레오티드 저해 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5457189A (ko) |
EP (1) | EP0637316A4 (ko) |
JP (2) | JP2609424B2 (ko) |
KR (1) | KR0160185B1 (ko) |
AU (1) | AU671630B2 (ko) |
CA (1) | CA2132424C (ko) |
FI (1) | FI944523A (ko) |
HU (1) | HUT69934A (ko) |
IL (1) | IL105241A0 (ko) |
NO (1) | NO943198L (ko) |
WO (1) | WO1993020095A1 (ko) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174870B1 (en) * | 1989-12-04 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
CN1043045C (zh) * | 1994-04-14 | 1999-04-21 | 同济医科大学 | 抑制内皮素生成的寡核苷酸及其应用 |
WO1995028942A1 (en) * | 1994-04-26 | 1995-11-02 | Genta Incorporated | Antisense oligomers for inhibiting human papillomaviruses |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
AU5738996A (en) * | 1995-05-11 | 1996-11-29 | Genetic Therapy, Inc. | Gene therapy through transduction of oral epithelial cells |
US6458940B2 (en) * | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
US6509149B2 (en) * | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
US7566455B1 (en) | 1995-06-07 | 2009-07-28 | Gpc Biotech, Inc. | E6AP-binding proteins |
US6111085A (en) * | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
EP0950097A2 (en) | 1996-12-27 | 1999-10-20 | Instituto de Investigaciones Bioquimicas Fundacion Campomar | Compositions and methods for tumour therapy |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6084090A (en) * | 1997-09-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Human papilloma virus anti-sense oligonucleotides |
AU2002300399C1 (en) * | 1997-09-05 | 2006-08-31 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus inhibition by anti-sense oligonucleotides |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
SK287538B6 (sk) | 1998-03-20 | 2011-01-04 | Commonwealth Scientific And Industrial Research Organisation | Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén |
US6306105B1 (en) * | 1998-05-14 | 2001-10-23 | Scimed Life Systems, Inc. | High performance coil wire |
WO1999060167A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
NZ508927A (en) | 1998-05-22 | 2003-12-19 | Ottawa Health Research Inst | Methods and products for inducing mucosal immunity |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) * | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
US6492111B1 (en) | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
JP2002541822A (ja) * | 1999-04-14 | 2002-12-10 | エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント | 組織特異的および病原体特異的毒性物質ならびにリボザイム |
JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US6641994B2 (en) | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
WO2001077294A2 (en) * | 2000-04-11 | 2001-10-18 | Origenix Technologies, Inc. | Hpv-specific short-mers |
US20020086849A1 (en) * | 2000-10-27 | 2002-07-04 | Gulilat Gebeyehu | Method for introducing antisense oligonucleotides into eucaryotic cells |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
DE10154831A1 (de) * | 2001-11-08 | 2003-06-05 | Deutsches Krebsforsch | PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen |
WO2004002416A2 (en) * | 2002-06-26 | 2004-01-08 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
BR0315810A (pt) | 2002-10-29 | 2005-09-13 | Coley Pharmaceutical Group Ltd | Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c |
EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
US20050123902A1 (en) * | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
AU2004275865B2 (en) | 2003-09-25 | 2008-09-25 | Third Wave Technologies, Inc. | Detection of HPV |
US8251110B2 (en) * | 2004-08-17 | 2012-08-28 | Mbhd, Llc | Filling adapter |
WO2006104381A1 (en) * | 2005-03-30 | 2006-10-05 | Labo Bio-Medical Investments | Identification of beta-papillomavirus dna by type-specific reverse hybridization |
WO2007038241A2 (en) * | 2005-09-22 | 2007-04-05 | Maine Medical Center Research | Modulation of mesenchymal and metastatic cell growth |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
US8080643B2 (en) * | 2006-09-05 | 2011-12-20 | Third Wave Technologies, Inc. | HPV primers |
EP2352830B1 (en) | 2008-10-03 | 2019-01-16 | CuRNA, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
US8921329B2 (en) | 2008-12-04 | 2014-12-30 | Curna, Inc. | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO |
US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
DK2396038T3 (en) | 2009-02-12 | 2016-02-01 | Curna Inc | TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF |
EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
US8791085B2 (en) | 2009-05-28 | 2014-07-29 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
EP2443237B1 (en) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
CA2770104C (en) | 2009-08-11 | 2019-03-19 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
JP5943836B2 (ja) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | ‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療 |
CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
NO2480669T3 (ko) | 2009-09-25 | 2018-04-07 | ||
JP6025567B2 (ja) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー,インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療 |
EP2516648B1 (en) | 2009-12-23 | 2017-11-08 | CuRNA, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
JP6031356B2 (ja) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
KR101853508B1 (ko) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | 종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료 |
CN102791862B (zh) | 2009-12-31 | 2017-04-05 | 库尔纳公司 | 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病 |
NO2521784T3 (ko) | 2010-01-04 | 2018-05-05 | ||
CN102822342B (zh) | 2010-01-06 | 2017-05-10 | 库尔纳公司 | 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病 |
US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
EP2539452B1 (en) | 2010-02-22 | 2016-07-27 | CuRNA, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
KR101877065B1 (ko) | 2010-04-02 | 2018-07-10 | 큐알엔에이, 인크. | 집락 자극 인자 3 (csf3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (csf3) 관련된 질환의 치료 |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
JP2013525483A (ja) | 2010-05-03 | 2013-06-20 | カッパーアールエヌエー,インコーポレイテッド | サーチュイン(sirt)に対する天然アンチセンス転写物の阻害によるサーチュイン(sirt)関連疾患の治療 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
WO2011150007A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
RU2588654C2 (ru) | 2010-06-23 | 2016-07-10 | Курна, Инк. | Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna |
EP2593547B1 (en) | 2010-07-14 | 2017-11-15 | CuRNA, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
CN103210086B (zh) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病 |
CN103180445B (zh) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病 |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
CN103874486A (zh) | 2011-09-06 | 2014-06-18 | 库尔纳公司 | 用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病 |
EP3169310A1 (en) | 2014-07-15 | 2017-05-24 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3625257A1 (de) * | 1986-07-23 | 1988-02-04 | Behringwerke Ag | Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika |
CA1339729C (en) * | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
CA2070664C (en) * | 1989-12-04 | 2000-08-08 | Christopher K. Mirabelli | Antisense oligonucleotide inhibition of papillomavirus |
CA2121144C (en) * | 1991-10-15 | 2001-07-31 | Phillip Dan Cook | Oligonucleotides having chiral phosphorus linkages |
JP2823959B2 (ja) * | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
-
1992
- 1992-03-31 US US07/860,925 patent/US5457189A/en not_active Expired - Lifetime
-
1993
- 1993-03-31 EP EP93908714A patent/EP0637316A4/en not_active Ceased
- 1993-03-31 HU HU9402822A patent/HUT69934A/hu unknown
- 1993-03-31 WO PCT/US1993/003075 patent/WO1993020095A1/en not_active Application Discontinuation
- 1993-03-31 CA CA002132424A patent/CA2132424C/en not_active Expired - Fee Related
- 1993-03-31 IL IL105241A patent/IL105241A0/xx unknown
- 1993-03-31 AU AU39438/93A patent/AU671630B2/en not_active Ceased
- 1993-03-31 JP JP5517699A patent/JP2609424B2/ja not_active Expired - Fee Related
- 1993-03-31 US US08/307,682 patent/US5665580A/en not_active Expired - Fee Related
- 1993-03-31 KR KR1019940703131A patent/KR0160185B1/ko not_active IP Right Cessation
-
1994
- 1994-08-29 NO NO943198A patent/NO943198L/no unknown
- 1994-09-29 FI FI944523A patent/FI944523A/fi not_active Application Discontinuation
- 1994-11-04 US US08/334,215 patent/US5681944A/en not_active Expired - Fee Related
-
1996
- 1996-08-14 JP JP8214477A patent/JP2737894B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI944523A0 (fi) | 1994-09-29 |
JPH09117291A (ja) | 1997-05-06 |
US5457189A (en) | 1995-10-10 |
HU9402822D0 (en) | 1995-01-30 |
IL105241A0 (en) | 1993-07-08 |
AU671630B2 (en) | 1996-09-05 |
NO943198D0 (no) | 1994-08-29 |
KR0160185B1 (ko) | 1998-11-16 |
AU3943893A (en) | 1993-11-08 |
EP0637316A1 (en) | 1995-02-08 |
WO1993020095A1 (en) | 1993-10-14 |
JP2737894B2 (ja) | 1998-04-08 |
US5681944A (en) | 1997-10-28 |
NO943198L (no) | 1994-08-29 |
EP0637316A4 (en) | 1997-07-16 |
JPH07501709A (ja) | 1995-02-23 |
HUT69934A (en) | 1995-09-28 |
JP2609424B2 (ja) | 1997-05-14 |
CA2132424C (en) | 2000-03-14 |
FI944523A (fi) | 1994-09-29 |
US5665580A (en) | 1997-09-09 |
CA2132424A1 (en) | 1993-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950700317A (ko) | 유두종 바이러스의 안티센스 올리고뉴클레오티드 저해(antisense oligonucleotide inhibition of papillomavirus) | |
EP0759979A4 (en) | ANTISENSE OLIGONUCLEOTIDES INHIBITION OF HEPATITIS C VIRUS | |
EP0837951A4 (en) | ANTISENSE INHIBITION OF HEPATITIS B VIRUS REPLICATION | |
PL321966A1 (en) | Vaccine against viral hepatitis of b type | |
LV11983A (lv) | Iekskigi lietojams 2-metil-tieno-benzodiazepina zalu preparats | |
ZA906621B (en) | Use of viruses against undesirable micro-organisms | |
AP9200412A0 (en) | Compounds and methods for inhibition of hiv and related viruses | |
BR1100839A (pt) | Gene homebox de interrupção de crescimento | |
DE69518743T2 (de) | Modifizierung von nukleotidanalogen | |
AU5850894A (en) | Novel agents for inhibition of hiv infectivity and use therefor | |
ITRM910890A0 (it) | Nuovi oligonucleotidi antisenso | |
TR199701051A3 (tr) | 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi | |
BR9607427A (pt) | Inibiçao de angiogêne usando interleucina 12 | |
EP0522081A4 (en) | Inhibition of disease associated with immunodeficiency virus infection | |
FI970765A (fi) | Dinukleotidi- ja oligonukleotidianalogien välituotteet | |
GB9018646D0 (en) | Replication of a eukaryotic virus rna | |
KR930701105A (ko) | 안티센스 올리고뉴클레오티드에 의한 헤르페스 비리대 감염의 억제 | |
ATA27793A (de) | Mehrschariger pflug | |
ATE240392T1 (de) | Spezifische oligonukleotide fuer hepatitis c- virus | |
DE69603473T2 (de) | Handhabung von drucktücher | |
IL127038A0 (en) | Inhibition of hiv-1 replication by antisense rna expression | |
AU3089892A (en) | Antiviral agent comprising antisense oligonucleotides complementary to the bhrf1 gene of epstein-barr virus | |
NO922169D0 (no) | Antisens oligonukleotidinhibisjon av papillomavirus | |
GB9621703D0 (en) | Composition for the treatment of conditions caused by herpes virus | |
IT1279547B1 (it) | Metodo per proteggere l'uso di un elaboratore elettronico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20010712 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |